Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 111 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
management of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
105
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane

NCT03930680
Conditions
Degradation of Top2b and Top2a in Human by Dexrazoxane, Time Course and Degradation of Top2b in Human by Dexrazoxane, Effects of Dexrazoxane on Healthy Human
Interventions
Dexrazoxane
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Cardiac Failure, Coronary Artery Disease, Sarcoidosis, Amyloidosis, Lupus, Myocarditis, Drug Toxicity
Interventions
Diagnostic Test: Myostrain
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Not listed
Enrollment
19 participants
Timeline
2019
U.S. locations
1
States / cities
Kansas City, Kansas
Not yet recruiting Phase 2 Interventional

The CARDIOPROTECT Trial

NCT07654426
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions
Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
Simvastatin, Doxorubicin/cyclophosphamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Conditions
Participants Undergoing Anthracycline Chemotherapy
Interventions
autoRIC®
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Terminated Phase 2 Interventional Results available

STOP Heart Disease in Breast Cancer Survivors Trial

NCT02674204
Conditions
Breast Cancer, Heart Disease, Cardiotoxicity, Myocardial Dysfunction
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Breast Cancer, HER2-positive Breast Cancer, HER2-positive Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Cardiotoxicity
Interventions
Cardiopulmonary Exercise Test, Echocardiogram, Echocardiography
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Chronic Lymphocytic Leukemia, Atrial Fibrillation, Hypertension, Cardiotoxicity
Interventions
no intervention
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
Coreg CR®, lisinopril, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
174
States / cities
Long Beach, California • Sylmar, California • Aurora, Colorado + 142 more
Conditions
Cancer, Cardiotoxicity
Interventions
Exercise program
Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
9 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
2
States / cities
Hartford, Connecticut • Columbus, Ohio
Conditions
Multiple Myeloma, Shortness of Breath, Dyspnea, Cardiotoxicity
Interventions
EndoPAT, Blood Pressure Cuff, Echocardiogram, Quality of Life Assessment, Blood Tests
Device · Diagnostic Test · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Terminated Phase 2 Interventional Results available

PROactive Evaluation of Function to Avoid CardioToxicity

NCT03862131
Conditions
Cardiotoxicity, Breast Cancer, Lymphoma, Sarcoma, Leukemia, Myeloma, Lung Cancer
Interventions
MyoStrain®
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
Interventions
Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more
Conditions
Breast Cancer, Breast Cancer, Female, Breast Cancer, Male, Breast Neoplasms
Interventions
Fluoro-D-glucose-positron Emission Tomography, 2-deoxy-2-[18F]fluoro-D-glucose (FDG), Echocardiogram
Diagnostic Test · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Interventions
15-minutes of sitting during COR ECG Acquistion
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Orange, California • Pasadena, California • Detroit, Michigan + 5 more
Conditions
Anthracycline Related Cardiotoxicity in Breast Cancer
Interventions
sulforaphane, Placebo Oral Tablet
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Lubbock, Texas
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphoid, Acute, Cardiotoxicity
Interventions
observation only
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
Interventions
TTP488, ddAC/ddT, TC, TCHP, Chemotherapy regimen that includes ddAC
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Conditions
Heart Failure, Multiple Myeloma
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Conditions
Breast Cancer, Cardiotoxicity, Cardiovascular Diseases
Interventions
High Intensity Interval Exercise, Moderate Intensity Walking
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
enalapril maleate, quality-of-life assessment
Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
8 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
55
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 43 more
Conditions
Neoplasms
Interventions
low dose CT
Diagnostic Test
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Conditions
Malignant Neoplasm
Interventions
Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas